Hanmi Pharmaceutical Co., Ltd.

Hanmi Pharmaceutical is a leading, R&D-centric biopharmaceutical company based in Seoul, South Korea, founded in 1973. The company is vertically integrated, with capabilities spanning the development of active pharmaceutical ingredients (APIs), intermediates, and finished products, and it maintains a strong focus on innovative drug discovery in oncology, metabolic diseases (diabetes, obesity), and rare diseases. Hanmi is recognized for its proprietary platform technologies, including 'LAPSCOVERY' for long-acting biologics and 'PENTAMBODY' for bispecific antibodies. The company actively pursues an 'Open Innovation' strategy, frequently entering into licensing and co-development agreements with global pharmaceutical partners to advance its pipeline and expand its international market presence.